ROS1 and non-small cell lung carcinoma: Targeted multiplexed panels able to analyze hot-spot regions of all approved molecular biomarker (such as EGFR, KRAS, BRAF, ALK, ROS1) are increasingly adopted across molecular pathology laboratories, according to the European Society for Medical Oncology (ESMO) recommendation for NSCLC [53].